Abstract
The process of prokaryotic drug discovery has been a model of success for over fifty years, yet the number of exploited bacterial targets is a mere fraction, less than 0.1% of the potential targets (based on total number of bacterial genes identified by gene sequence projects). To better understand the potential for drug intervention, multiple paradigms have been established in the pharmaceutical industry, all with some semblance of commonality and uniqueness to provide proprietary positioning, yet no company has been successful to date in taking a ‘genomics approach’ to the finish line of having a genomics-based drug on the market. Within this overview, we provide a strategic overview of a sample process for the identification, validation and exploitation of novel antibacterial targets ascertained through a bioinformatics-based genomics drug discovery program.
Keywords: microbial genomics, antibiotic discovery, prokaryotic drug, genomics approach, genomics-based drug
Current Pharmaceutical Design
Title: Microbial Genomics and Novel Antibiotic Discovery: New Technology to Search for New Drugs
Volume: 8 Issue: 13
Author(s): Thomas J. Dougherty, John F. Barrett and Michael J. Pucci
Affiliation:
Keywords: microbial genomics, antibiotic discovery, prokaryotic drug, genomics approach, genomics-based drug
Abstract: The process of prokaryotic drug discovery has been a model of success for over fifty years, yet the number of exploited bacterial targets is a mere fraction, less than 0.1% of the potential targets (based on total number of bacterial genes identified by gene sequence projects). To better understand the potential for drug intervention, multiple paradigms have been established in the pharmaceutical industry, all with some semblance of commonality and uniqueness to provide proprietary positioning, yet no company has been successful to date in taking a ‘genomics approach’ to the finish line of having a genomics-based drug on the market. Within this overview, we provide a strategic overview of a sample process for the identification, validation and exploitation of novel antibacterial targets ascertained through a bioinformatics-based genomics drug discovery program.
Export Options
About this article
Cite this article as:
Dougherty J. Thomas, Barrett F. John and Pucci J. Michael, Microbial Genomics and Novel Antibiotic Discovery: New Technology to Search for New Drugs, Current Pharmaceutical Design 2002; 8 (13) . https://dx.doi.org/10.2174/1381612023394782
DOI https://dx.doi.org/10.2174/1381612023394782 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenetics of Alcohol and Alcohol Dependence Treatment
Current Pharmaceutical Design Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Tissue Doppler Imaging: Beautiful Noise
Current Cardiology Reviews Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy
Current Gene Therapy N-Substituted Aryl Sulphonamides as Potential Anti-Alzheimer’s Agents: Design, Synthesis and Biological Evaluation
Current Computer-Aided Drug Design Trigeminal Neuralgia: Basic and Clinical Aspects
Current Neuropharmacology The Yin and Yang of BK Channels in Epilepsy
CNS & Neurological Disorders - Drug Targets Beyond the Cardiac Myofilament: Hypertrophic Cardiomyopathy- Associated Mutations in Genes that Encode Calcium-Handling Proteins
Current Molecular Medicine Pharmaceuticals and Cosmeceuticals Based on Soft Nanotechnology Techniques with Antioxidative, Immunostimulative and other Therapeutic Activities
Recent Patents on Nanotechnology Antibiotic Treatment in Native Valve Infective Endocarditis
Infectious Disorders - Drug Targets Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry Changes in Serum Amino Acids in Migraine Patients without and with Aura and their Possible Usefulness in the Study of Migraine Pathogenesis
CNS & Neurological Disorders - Drug Targets Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier
Current Pharmaceutical Design A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: COMT as a Drug Target for Nervous System Disorders (Guest Editor: Francesco Papaleo)]
CNS & Neurological Disorders - Drug Targets Concentration-Dependent Bimodal Effect of Specific 18 kDa Translocator Protein (TSPO) Ligands on Cell Death Processes Induced by Ammonium Chloride: Potential Implications for Neuropathological Effects Due to Hyperammonemia
CNS & Neurological Disorders - Drug Targets Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry A Review of the Most Important Classes of Serine Protease Inhibitors in Insects and Leeches
Medicinal Chemistry Reviews - Online (Discontinued) Beta-Adrenoreceptor Modulation of Metabolic, Endocrine and Immunologic Function During Critical Illness
Endocrine, Metabolic & Immune Disorders - Drug Targets Plasma Acetylcholinesterase Activity Correlates with Intracerebral β-Amyloid Load
Current Alzheimer Research